TNDM vs. ATEC, ATRC, NVCR, NARI, ICUI, LMAT, PRCT, MDXG, IART, and FNA
Should you be buying Tandem Diabetes Care stock or one of its competitors? The main competitors of Tandem Diabetes Care include Alphatec (ATEC), AtriCure (ATRC), NovoCure (NVCR), Inari Medical (NARI), ICU Medical (ICUI), LeMaitre Vascular (LMAT), PROCEPT BioRobotics (PRCT), MiMedx Group (MDXG), Integra LifeSciences (IART), and Paragon 28 (FNA). These companies are all part of the "surgical & medical instruments" industry.
Alphatec (NASDAQ:ATEC) and Tandem Diabetes Care (NASDAQ:TNDM) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, risk, dividends, valuation, media sentiment, earnings and community ranking.
Alphatec has a beta of 1.58, suggesting that its share price is 58% more volatile than the S&P 500. Comparatively, Tandem Diabetes Care has a beta of 1.08, suggesting that its share price is 8% more volatile than the S&P 500.
Alphatec has higher earnings, but lower revenue than Tandem Diabetes Care. Tandem Diabetes Care is trading at a lower price-to-earnings ratio than Alphatec, indicating that it is currently the more affordable of the two stocks.
67.2% of Alphatec shares are owned by institutional investors. 29.1% of Alphatec shares are owned by company insiders. Comparatively, 2.5% of Tandem Diabetes Care shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Tandem Diabetes Care has a net margin of -29.77% compared to Tandem Diabetes Care's net margin of -38.70%. Tandem Diabetes Care's return on equity of 0.00% beat Alphatec's return on equity.
Alphatec currently has a consensus target price of $22.75, suggesting a potential upside of 68.39%. Tandem Diabetes Care has a consensus target price of $36.00, suggesting a potential upside of 15.68%. Given Tandem Diabetes Care's stronger consensus rating and higher probable upside, equities research analysts plainly believe Alphatec is more favorable than Tandem Diabetes Care.
In the previous week, Tandem Diabetes Care had 4 more articles in the media than Alphatec. MarketBeat recorded 10 mentions for Tandem Diabetes Care and 6 mentions for Alphatec. Alphatec's average media sentiment score of 1.28 beat Tandem Diabetes Care's score of 0.83 indicating that Tandem Diabetes Care is being referred to more favorably in the news media.
Tandem Diabetes Care received 252 more outperform votes than Alphatec when rated by MarketBeat users. Likewise, 61.04% of users gave Tandem Diabetes Care an outperform vote while only 56.28% of users gave Alphatec an outperform vote.
Summary
Alphatec beats Tandem Diabetes Care on 11 of the 18 factors compared between the two stocks.
Get Tandem Diabetes Care News Delivered to You Automatically
Sign up to receive the latest news and ratings for TNDM and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding TNDM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartThis chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Tandem Diabetes Care Competitors List
Related Companies and Tools